Blocking the expression of IL-6 or its receptor to the perturb IL-6 signaling pathway results in a reduction in the risk of coronary artery disease and atrial fibrillation, as well as T2D [31]. The gene discussed is IL6; the disease is type 2 diabetes mellitus.